The commitment from both new and existing investors provide us with the assets to progress our regulatory efforts, plan a successful release of octreotide capsules, test oral octreotide capsules for extra indications and further invest in earlier-stage TPE programs that can fuel our development over the long term, stated Roni Mamluk, Ph.D., chief executive officer of Chiasma. With this financing in place, we are well positioned to advance a portfolio of oral medications that address unmet requirements in orphan indications. .. Chiasma closes $70 million Series E financing round Chiasma, Inc., a U.S. Privately-held biopharma organization developing octreotide capsules, its business lead item for the orphan condition acromegaly, today announced the closing of a $70 million Series E funding round.Related StoriesEnvision inaugurates 10th Annual Meeting, honors outstanding achievements in low vision rehabilitationUAB optometrist offers tips to keep eyes healthful during summer monthsQUT's Professor Joanne Hardwood wins 'Nobel Prize' of international optometry No Signs of Protection Issues with Melimine-Coated Lenses in Human Eye The only significant difference was elevated staining of the cornea caused by melimine-coated lenses. Comfort rankings were similar between your two lenses-simply one volunteer reported pain with the covered lenses. No delayed reactions happened after putting on melimine-coated lenses.